Flaviviruses are a group of positive-stranded RNA viruses that have a global impact on public health due to their widespread distribution and ability to cause severe disease in humans. Several viruses in this genus, such as dengue and West Nile viruses (DENV and WNV, respectively), are considered emerging or re-emerging pathogens due to significant increases in morbidity and mortality observed during the past decade. Each year, 50-100 million individuals are infected by one of the four serotypes of DENV, resulting in roughly 250,000 cases of a severe and potentially fatal hemorrhagic manifestation of the disease. WNV is an encephalitic flavivirus introduced into North America in 1999 that has subsequently spread across the continent resulting in more than 29,000 reported clinical cases and approximately 1,100 fatalities (www.cdc.gov). While the clinical burden of WNV appears modest by comparison to other viral infectious diseases, long-term studies of morbidity in individuals that survive acute WNV infection suggest the true clinical burden of WNV disease in North America may not yet be realized. Humoral immunity is a critical aspect of host protection against flaviviruses;eliciting protective antibodies is a primary focus of ongoing vaccine development efforts for several of these viruses, including WNV and DENV. Complicating these efforts is the potential for antibodies elicited by natural infection or vaccination to modulate DENV pathogenesis and enhance disease. Antibody-dependent enhancement of infection (ADE) describes a dramatic increase in the infection of Fc-gamma-receptor-bearing cells in the presence of sub-neutralizing concentrations of antibody or immune sera. The biochemical and functional properties of a protective antibody response are not known. A primary goal of the Viral Pathogenesis Section is to understand the mechanisms of humoral immunity against flaviviruses. We are investigating the molecular and structural basis of antibody-mediated neutralization and enhancement of flavivirus infection, while working to apply the knowledge and perspectives arising from these studies towards dissecting the functional properties of the polyclonal antibody response of naturally infected and vaccinated humans.

Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Zip Code
Goo, Leslie; VanBlargan, Laura A; Dowd, Kimberly A et al. (2017) A single mutation in the envelope protein modulates flavivirus antigenicity, stability, and pathogenesis. PLoS Pathog 13:e1006178
Zhang, Rong; Miner, Jonathan J; Gorman, Matthew J et al. (2016) A CRISPR screen defines a signal peptide processing pathway required by flaviviruses. Nature 535:164-8
Mukherjee, Swati; Sirohi, Devika; Dowd, Kimberly A et al. (2016) Enhancing dengue virus maturation using a stable furin over-expressing cell line. Virology 497:33-40
Dowd, Kimberly A; DeMaso, Christina R; Pierson, Theodore C (2015) Genotypic Differences in Dengue Virus Neutralization Are Explained by a Single Amino Acid Mutation That Modulates Virus Breathing. MBio 6:e01559-15
Goo, Leslie; Pierson, Theodore C (2015) Dengue virus: Bumps in the road to therapeutic antibodies. Nature 524:295-6
Pierson, Theodore C; Diamond, Michael S (2015) A game of numbers: the stoichiometry of antibody-mediated neutralization of flavivirus infection. Prog Mol Biol Transl Sci 129:141-66
VanBlargan, Laura A; Davis, Kaitlin A; Dowd, Kimberly A et al. (2015) Context-Dependent Cleavage of the Capsid Protein by the West Nile Virus Protease Modulates the Efficiency of Virus Assembly. J Virol 89:8632-42
Diamond, Michael S; Pierson, Theodore C (2015) Molecular Insight into Dengue Virus Pathogenesis and Its Implications for Disease Control. Cell 162:488-92
Kuhn, Richard J; Dowd, Kimberly A; Beth Post, Carol et al. (2015) Shake, rattle, and roll: Impact of the dynamics of flavivirus particles on their interactions with the host. Virology 479-480:508-17
Edeling, Melissa A; Austin, S Kyle; Shrestha, Bimmi et al. (2014) Potent dengue virus neutralization by a therapeutic antibody with low monovalent affinity requires bivalent engagement. PLoS Pathog 10:e1004072

Showing the most recent 10 out of 35 publications